1992
DOI: 10.1507/endocrj1954.39.325
|View full text |Cite
|
Sign up to set email alerts
|

Effects of the Protein Phosphatase Inhibitors Okadaic Acid and Calyculin A on Insulin Release from Rat Pancreatic Islets.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
11
0

Year Published

1996
1996
2007
2007

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(14 citation statements)
references
References 12 publications
3
11
0
Order By: Relevance
“…The data from the present study suggest further that inhibition of glucose-induced insulin release from isolated islets by OA, as observed by Tamagawa et al (1992) and Ratcliff and Jones (1993) is, at least partly, due to prevention of the elevation of [ -Ca2 +]i following Ca 2+ influx across the plasma membrane.…”
Section: Oa and [Ca2+]isupporting
confidence: 80%
See 1 more Smart Citation
“…The data from the present study suggest further that inhibition of glucose-induced insulin release from isolated islets by OA, as observed by Tamagawa et al (1992) and Ratcliff and Jones (1993) is, at least partly, due to prevention of the elevation of [ -Ca2 +]i following Ca 2+ influx across the plasma membrane.…”
Section: Oa and [Ca2+]isupporting
confidence: 80%
“…Recently, it has been observed that insulin secretion in response to glucose, glyceraldehyde and KC1 is inhibited by okadaic acid (OA), a potent inhibitor of protein phosphatase-1 (PP-1) and -2A (PP-2A), in rat pancreatic islets (Tamagawa et al 1992;Ratcliff and Jones 1993). On the other hand, when the adenylate cyclase activator forskolin is introduced OA even acts synergistically in mouse pancreatic fi cells (~mm~ilfi et al 1994) and RINm5F cells (Mayer et al 1994) whereas OA decreased forskolin-or 4/%phorbolmyristate acetate (PMA)-potentiated insulin release in rat islets (Tamagawa et al 1992 andRatcliff andJones 1993). Taking these different actions of OA in consideration, it seems possible that phosphorylations of proteins related to insulin release are located at different steps in the secretory machinery -in the initiation or in the modulation site -and it is also possible that phosphorylation of such proteins may produce variable actions in insulin secretion.…”
Section: Introductionmentioning
confidence: 99%
“…First, using isotope-labeling methods and vapor-phase equilibration assay, we have demonstrated that post-translational CML of PP2Ac is necessary for insulin secretion [5,8]. Second, several earlier studies have utilized specific inhibitors of PP2A, such as OKA to examine its role in insulin-secretion [24][25][26][27][28][29], and indeed, we have also demonstrated that OKA specifically inhibits the CML of PP2Ac [5,8]. Together, these findings implicate a principal role for PP2Ac in islet function.…”
Section: Discussionsupporting
confidence: 57%
“…For example, okadaic acid (OKA), a selective inhibitor of protein phosphatases, stimulates basal and cAMP-stimulated insulin secretion from electrically permeabilized islets (31). There is also evidence to indicate inhibition by OKA of glucose, glyceraldehyde, and KCl-stimulated insulin secretion from the ␤-cell (2,40). These findings thus implicate protein (de)phosphorylation in insulin secretion.…”
mentioning
confidence: 99%
“…Although several previous studies were focused on the identification and characterization of protein kinases in islets (4, 11, 16), little information is available on the localization and regulation of phosphoprotein phosphatases in the pancreatic ␤-cell. With use of relatively specific inhibitors of protein phosphatase function, recent studies (1,2,23,31,36,40) have suggested important roles for various phosphoprotein phosphatases, such as protein phosphatase 2A (PP2A), in the pancreatic ␤-cell function. For example, okadaic acid (OKA), a selective inhibitor of protein phosphatases, stimulates basal and cAMP-stimulated insulin secretion from electrically permeabilized islets (31).…”
mentioning
confidence: 99%